DOCK7 Genotype

DOCK7 (dedicator of cytokinesis 7) is a gene with two very different stories. Rare loss-of-function variants in this gene can cause a severe childhood epilepsy syndrome with developmental delay and vision problems. Common variants in the same chromosomal region show up in studies of blood fat levels and coronary artery disease, though the lipid connection likely reflects a separate gene (ANGPTL3) that is physically embedded within DOCK7's genomic structure.

This is a one-time genetic test. Your DOCK7 sequence does not change over your lifetime, so knowing your status once can inform decisions about family planning, pediatric workups, and how aggressively to monitor heart and lipid risk. The result is most clinically meaningful when there is a personal or family history of severe early-onset seizures, or when standard cardiovascular labs do not fully explain a family pattern of heart disease.

What DOCK7 Actually Does

DOCK7 sits on chromosome 1 (specifically at 1p31) and codes for a signaling protein in brain cells. It acts as a switch (called a guanine nucleotide exchange factor) that turns on smaller proteins involved in shaping neurons. Specifically, it helps young brain cells grow long projections called axons, the wires that let neurons talk to each other.

The protein is most active in the developing brain, where it controls how neural stem cells divide and migrate to form the cortex. Without working DOCK7, axons do not form properly, brain wiring gets disrupted, and severe neurological problems can follow. The DOCK7 protein itself has no known role in cholesterol or fat handling. However, the DOCK7 genomic region does play a regulatory role in lipid metabolism because it physically contains the ANGPTL3 gene within one of its introns.

Severe Childhood Epilepsy (EIEE23)

When both copies of DOCK7 carry damaging mutations (either inherited from each parent, or both inherited from one parent through a rare chromosomal event), the result is early infantile epileptic encephalopathy type 23. This is an autosomal recessive condition, meaning carriers with only one damaged copy are typically unaffected, but two damaged copies cause disease.

Children with EIEE23 develop seizures in infancy that are often hard to control with standard medications. They also show developmental delay, intellectual disability, and cortical visual impairment, which means the eyes work but the brain cannot fully process what they see. Brain imaging often reveals underdeveloped brainstem structures and changes in the back of the brain.

The variants reported so far are mostly truncating mutations that shorten the protein and eliminate its function. In one published case, a child inherited a frameshift variant from her mother on both copies of chromosome 1 through a rare genetic mechanism called segmental uniparental isodisomy. This illustrates that you do not always need two carrier parents to develop the disease.

Lipid Levels and Coronary Artery Disease

Common DOCK7 variants have been studied for their statistical link to blood lipids and heart disease, mostly in Chinese populations. In a study of 1,869 Chinese adults (881 Jing and 988 Han participants), several DOCK7 variants were associated with differences in triglycerides, LDL cholesterol, HDL cholesterol, and the apolipoproteins ApoA1 and ApoB.

In a separate study of 1,728 Southern Chinese Han adults, one specific DOCK7 variant called rs1748195 showed up more often in people with coronary artery disease than in healthy controls (27.6% versus 23.6% carried the G allele). The variant remained linked to higher heart disease risk and more severe coronary artery narrowing on imaging even after accounting for other risk factors.

Why the Lipid Connection Works This Way

Here is where it gets interesting. DOCK7's actual biological job is in brain development, not fat metabolism. The key fact is that ANGPTL3, a gene that genuinely controls how the body handles fats, is located entirely within an intron of DOCK7. The two genes are physically nested together in the same stretch of DNA. When a genetic variant in DOCK7 tracks with cholesterol levels, it most likely reflects a non-coding regulatory effect on ANGPTL3 expression rather than a change in DOCK7 protein function.

This is a useful reminder that statistical association is not the same as direct biological cause. Your DOCK7 variant may flag a region of DNA worth watching for cardiovascular risk, but the mechanism likely runs through ANGPTL3 regulation rather than DOCK7 itself. The practical implication: if your test flags a lipid-associated DOCK7 variant, the next step is to check your actual lipid panel and ApoB, not to assume DOCK7 protein is acting on your blood fats.

Why This Is a One-Time Test

DOCK7 is a fixed part of your genome. The sequence you inherit at conception is the sequence you carry for life, in every cell. There is no reason to retest your DOCK7 genotype once you have a confirmed result from a reliable lab. What does change over time is what we know about the gene and what tools exist to act on the result.

The value of this test comes from integrating the result into decisions over years, not from repeating the measurement. If you carry one copy of a damaging variant, that matters for family planning. If common variants flag possible cardiovascular risk, that should prompt regular lipid panels, ApoB testing, and possibly coronary artery calcium scoring rather than repeat genetic testing.

When Results Can Be Misleading

Genetic tests have their own confounders that differ from standard blood work.

• Variant panel coverage: the test only reads the specific positions it is designed to read. A result showing no risk variants does not rule out rare or undescribed mutations in DOCK7 that the panel does not check for.
• Population frequency differences: most published lipid and cardiovascular data on DOCK7 come from Chinese cohorts. The same variant may be more or less common, or carry a different risk weight, in people of other ancestries.
• Variants of uncertain significance: an unexpected DOCK7 change may be reported with unclear meaning. This does not confirm disease risk, and a genetic counselor can help interpret it.
• Direct-to-consumer versus clinical testing: results from a 23andMe-style report covering DOCK7 should be confirmed with a clinical-grade test before being used to make medical decisions.

Decision Pathway for an Out-of-Pattern Result

If your DOCK7 test flags a known pathogenic variant, the next steps depend on which type. For carriers of one damaging variant, the priority is genetic counseling, especially if you are planning to have children. Your partner can be tested to assess whether your future children could inherit two damaged copies. For homozygous or compound heterozygous findings in a child with seizures, confirmation by a second method and immediate involvement of a pediatric neurologist or geneticist is appropriate.

If your result flags a common DOCK7 variant linked to lipid or cardiovascular risk, treat it as a prompt to look harder at your standard cardiovascular workup. Order an ApoB if you have not, check Lp(a) once in your lifetime, and consider a coronary artery calcium score if you are over 40 or have other risk factors. The genetic finding does not replace these tests. It tells you to take them more seriously.

Family Implications

Because DOCK7 variants are inherited, any finding has implications for biological relatives. Siblings of someone with two damaging copies have a 1 in 4 chance of also being affected and a 1 in 2 chance of being a silent carrier. Parents of an affected child are almost always carriers themselves. Adult relatives carrying lipid-associated variants share the same flag for heart disease risk and may benefit from earlier cardiovascular screening.